+1,735.1%
PLTR vs GSK
+69.6%
+1,665.5%
-84.6%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -4.5% | -1.9% | -2.6% | -4.5% |
| 7D | -6.4% | -1.8% | -4.6% | -6.4% |
| 30D | +10.0% | -2.2% | +12.2% | +10.1% |
| 3M | +23.0% | -1.8% | +24.8% | +23.0% |
| 6M | +13.8% | -10.6% | +24.4% | +13.9% |
| YTD | -1.9% | +4.4% | -6.3% | -2.5% |
| 1Y | +11.6% | +30.4% | -18.8% | +9.6% |
| 3Y | +1,048.4% | +60.1% | +988.4% | +1,008.2% |
| 5Y | +554.4% | +46.8% | +507.6% | +535.2% |
| All | +1,735.1% | +69.6% | +1,665.5% | +1,603.6% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling